Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIAO: Durvalumab +/- Tremelimumab in Oropharyngeal Carcinoma
NCT03144778Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2017
- Primary completion
- Mar 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in oropharyngeal squamous cell carcinoma (OPSCC) comparing Durvalumab with Durvalumab + Tremelimumab (2 arms). Primary endpoint: Change of CD8+ tumor infiltrating lymphocytes. Started Jul 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03144778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144778.